Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Discovery of Tarantula Venom-Derived NaV1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis.

Wu B, Murray JK, Andrews KL, Sham K, Long J, Aral J, Ligutti J, Amagasu S, Liu D, Zou A, Min X, Wang Z, Ilch CP, Kornecook TJ, Lin MJ, Be X, Miranda LP, Moyer BD, Biswas K.

J Med Chem. 2018 Oct 22. doi: 10.1021/acs.jmedchem.8b00736. [Epub ahead of print]

PMID:
30346167
2.

Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V.

Moyer BD, Murray JK, Ligutti J, Andrews K, Favreau P, Jordan JB, Lee JH, Liu D, Long J, Sham K, Shi L, Stöcklin R, Wu B, Yin R, Yu V, Zou A, Biswas K, Miranda LP.

PLoS One. 2018 May 3;13(5):e0196791. doi: 10.1371/journal.pone.0196791. eCollection 2018.

3.

1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition.

Boezio AA, Andrews K, Boezio C, Chu-Moyer M, Copeland KW, DiMauro EF, Foti RS, Fremeau RT Jr, Gao H, Geuns-Meyer S, Graceffa RF, Gunaydin H, Huang H, La DS, Ligutti J, Moyer BD, Peterson EA, Yu V, Weiss MM.

Bioorg Med Chem Lett. 2018 Jun 15;28(11):2103-2108. doi: 10.1016/j.bmcl.2018.04.035. Epub 2018 Apr 17.

PMID:
29709252
4.

Engineering Antibody Reactivity for Efficient Derivatization to Generate NaV1.7 Inhibitory GpTx-1 Peptide-Antibody Conjugates.

Biswas K, Nixey TE, Murray JK, Falsey JR, Yin L, Liu H, Gingras J, Hall BE, Herberich B, Holder JR, Li H, Ligutti J, Lin MJ, Liu D, Soriano BD, Soto M, Tran L, Tegley CM, Zou A, Gunasekaran K, Moyer BD, Doherty L, Miranda LP.

ACS Chem Biol. 2017 Sep 15;12(9):2427-2435. doi: 10.1021/acschembio.7b00542. Epub 2017 Aug 28.

PMID:
28800217
5.

Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.

Schenkel LB, DiMauro EF, Nguyen HN, Chakka N, Du B, Foti RS, Guzman-Perez A, Jarosh M, La DS, Ligutti J, Milgram BC, Moyer BD, Peterson EA, Roberts J, Yu VL, Weiss MM.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3817-3824. doi: 10.1016/j.bmcl.2017.06.054. Epub 2017 Jun 26.

PMID:
28684121
6.

The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement.

La DS, Peterson EA, Bode C, Boezio AA, Bregman H, Chu-Moyer MY, Coats J, DiMauro EF, Dineen TA, Du B, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Fremeau R Jr, Huang X, Ilch C, Kornecook TJ, Kreiman C, Ligutti J, Jasmine Lin MH, McDermott JS, Marx I, Matson DJ, McDonough SI, Moyer BD, Nho Nguyen H, Taborn K, Yu V, Weiss MM.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3477-3485. doi: 10.1016/j.bmcl.2017.05.070. Epub 2017 Jun 1.

PMID:
28629594
7.

Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7.

Kornecook TJ, Yin R, Altmann S, Be X, Berry V, Ilch CP, Jarosh M, Johnson D, Lee JH, Lehto SG, Ligutti J, Liu D, Luther J, Matson D, Ortuno D, Roberts J, Taborn K, Wang J, Weiss MM, Yu V, Zhu DXD, Fremeau RT Jr, Moyer BD.

J Pharmacol Exp Ther. 2017 Jul;362(1):146-160. doi: 10.1124/jpet.116.239590. Epub 2017 May 4.

8.

Correction to "Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement".

Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT Jr, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MJ, Liu D, McDermott JS, Moyer BD, Nguyen HN, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM.

ACS Med Chem Lett. 2017 Feb 28;8(3):378. doi: 10.1021/acsmedchemlett.7b00075. eCollection 2017 Mar 9.

9.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT Jr, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM.

J Med Chem. 2017 Jul 27;60(14):5990-6017. doi: 10.1021/acs.jmedchem.6b01850. Epub 2017 Apr 20.

PMID:
28324649
10.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin MJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT Jr.

J Med Chem. 2017 Jul 27;60(14):5969-5989. doi: 10.1021/acs.jmedchem.6b01851. Epub 2017 Apr 20.

PMID:
28287723
11.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement.

Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT Jr, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MJ, Liu D, McDermott JS, Moyer BD, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM.

ACS Med Chem Lett. 2016 Sep 21;7(12):1062-1067. eCollection 2016 Dec 8. Erratum in: ACS Med Chem Lett. 2017 Feb 28;8(3):378.

12.

Evaluation of recombinant monoclonal antibody SVmab1 binding to Na V1.7 target sequences and block of human Na V1.7 currents.

Liu D, Tseng M, Epstein LF, Green L, Chan B, Soriano B, Lim D, Pan O, Murawsky CM, King CT, Moyer BD.

F1000Res. 2016 Nov 25;5:2764. eCollection 2016.

13.

Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in rats.

Lehto SG, Weyer AD, Youngblood BD, Zhang M, Yin R, Wang W, Teffera Y, Cooke M, Stucky CL, Schenkel L, Geuns-Meyer S, Moyer BD, Wild KD, Gavva NR.

Mol Pain. 2016 Nov 29;12. pii: 1744806916677761. Print 2016.

14.

Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Sparling BA, Yi S, Able J, Bregman H, DiMauro EF, Foti RS, Gao H, Guzman-Perez A, Huang H, Jarosh M, Kornecook T, Ligutti J, Milgram BC, Moyer BD, Youngblood B, Yu VL, Weiss MM.

Medchemcomm. 2016 Dec 2;8(4):744-754. doi: 10.1039/c6md00578k. eCollection 2017 Apr 1.

15.

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Bojic EF, Foti RS, Fremeau R, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, Kornecook T, Lee J, Ligutti J, Liu D, Moyer BD, Ortuno D, Rose PE, Schenkel LB, Taborn K, Wang J, Wang Y, Yu V, Weiss MM.

J Med Chem. 2016 Sep 8;59(17):7818-39. doi: 10.1021/acs.jmedchem.6b00425. Epub 2016 Aug 29.

PMID:
27441383
16.

Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1.

Murray JK, Long J, Zou A, Ligutti J, Andrews KL, Poppe L, Biswas K, Moyer BD, McDonough SI, Miranda LP.

J Med Chem. 2016 Mar 24;59(6):2704-17. doi: 10.1021/acs.jmedchem.5b01947. Epub 2016 Mar 10.

PMID:
26890998
17.

Sustained inhibition of the NaV1.7 sodium channel by engineered dimers of the domain II binding peptide GpTx-1.

Murray JK, Biswas K, Holder JR, Zou A, Ligutti J, Liu D, Poppe L, Andrews KL, Lin FF, Meng SY, Moyer BD, McDonough SI, Miranda LP.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4866-4871. doi: 10.1016/j.bmcl.2015.06.033. Epub 2015 Jun 16.

PMID:
26112439
18.

Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.

Murray JK, Ligutti J, Liu D, Zou A, Poppe L, Li H, Andrews KL, Moyer BD, McDonough SI, Favreau P, Stöcklin R, Miranda LP.

J Med Chem. 2015 Mar 12;58(5):2299-314. doi: 10.1021/jm501765v. Epub 2015 Feb 19.

PMID:
25658507
19.

Voltage-gated sodium channel function and expression in injured and uninjured rat dorsal root ganglia neurons.

Yin R, Liu D, Chhoa M, Li CM, Luo Y, Zhang M, Lehto SG, Immke DC, Moyer BD.

Int J Neurosci. 2016;126(2):182-92. doi: 10.3109/00207454.2015.1004172. Epub 2015 Apr 7.

PMID:
25562420
20.

Global Nav1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain.

Gingras J, Smith S, Matson DJ, Johnson D, Nye K, Couture L, Feric E, Yin R, Moyer BD, Peterson ML, Rottman JB, Beiler RJ, Malmberg AB, McDonough SI.

PLoS One. 2014 Sep 4;9(9):e105895. doi: 10.1371/journal.pone.0105895. eCollection 2014.

21.

Expression of genes encoding multi-transmembrane proteins in specific primate taste cell populations.

Moyer BD, Hevezi P, Gao N, Lu M, Kalabat D, Soto H, Echeverri F, Laita B, Yeh SA, Zoller M, Zlotnik A.

PLoS One. 2009 Dec 4;4(12):e7682. doi: 10.1371/journal.pone.0007682.

22.

Genome-wide analysis of gene expression in primate taste buds reveals links to diverse processes.

Hevezi P, Moyer BD, Lu M, Gao N, White E, Echeverri F, Kalabat D, Soto H, Laita B, Li C, Yeh SA, Zoller M, Zlotnik A.

PLoS One. 2009 Jul 28;4(7):e6395. doi: 10.1371/journal.pone.0006395.

23.

Voltage-gated sodium channels in taste bud cells.

Gao N, Lu M, Echeverri F, Laita B, Kalabat D, Williams ME, Hevezi P, Zlotnik A, Moyer BD.

BMC Neurosci. 2009 Mar 12;10:20. doi: 10.1186/1471-2202-10-20.

24.

Small molecule activator of the human epithelial sodium channel.

Lu M, Echeverri F, Kalabat D, Laita B, Dahan DS, Smith RD, Xu H, Staszewski L, Yamamoto J, Ling J, Hwang N, Kimmich R, Li P, Patron E, Keung W, Patron A, Moyer BD.

J Biol Chem. 2008 May 2;283(18):11981-94. doi: 10.1074/jbc.M708001200. Epub 2008 Mar 6.

25.
26.

Endoplasmic reticulum degradation impedes olfactory G-protein coupled receptor functional expression.

Lu M, Staszewski L, Echeverri F, Xu H, Moyer BD.

BMC Cell Biol. 2004 Sep 15;5:34.

27.
28.

Analysis of CFTR trafficking and polarization using green fluorescent protein and confocal microscopy.

Moyer BD, Stanton BA.

Methods Mol Med. 2002;70:217-27. No abstract available.

PMID:
11917525
29.

Non-conventional trafficking of the cystic fibrosis transmembrane conductance regulator through the early secretory pathway.

Yoo JS, Moyer BD, Bannykh S, Yoo HM, Riordan JR, Balch WE.

J Biol Chem. 2002 Mar 29;277(13):11401-9. Epub 2002 Jan 17.

30.

A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression.

Cheng J, Moyer BD, Milewski M, Loffing J, Ikeda M, Mickle JE, Cutting GR, Li M, Stanton BA, Guggino WB.

J Biol Chem. 2002 Feb 1;277(5):3520-9. Epub 2001 Nov 13.

31.

Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression.

Maitra R, Halpin PA, Karlson KH, Page RL, Paik DY, Leavitt MO, Moyer BD, Stanton BA, Hamilton JW.

Biochem J. 2001 May 1;355(Pt 3):617-24.

32.
33.

Expression of wild-type and mutant green fluorescent protein-Rab1 for fluorescence microscopy analysis.

Moyer BD, Matteson J, Balch WE.

Methods Enzymol. 2001;329:6-14. No abstract available.

PMID:
11210573
34.

Structural basis for Rab function: an overview.

Moyer BD, Balch WE.

Methods Enzymol. 2001;329:3-6. Review. No abstract available.

PMID:
11210547
35.

Traffic pattern of cystic fibrosis transmembrane regulator through the early exocytic pathway.

Bannykh SI, Bannykh GI, Fish KN, Moyer BD, Riordan JR, Balch WE.

Traffic. 2000 Nov;1(11):852-70.

36.

A PDZ-binding motif is essential but not sufficient to localize the C terminus of CFTR to the apical membrane.

Milewski MI, Mickle JE, Forrest JK, Stafford DM, Moyer BD, Cheng J, Guggino WB, Stanton BA, Cutting GR.

J Cell Sci. 2001 Feb;114(Pt 4):719-26.

37.

Functional and molecular characterization of an anion exchanger in airway serous epithelial cells.

Loffing J, Moyer BD, Reynolds D, Shmukler BE, Alper SL, Stanton BA.

Am J Physiol Cell Physiol. 2000 Oct;279(4):C1016-23.

38.
39.

The PDZ-interacting domain of cystic fibrosis transmembrane conductance regulator is required for functional expression in the apical plasma membrane.

Moyer BD, Duhaime M, Shaw C, Denton J, Reynolds D, Karlson KH, Pfeiffer J, Wang S, Mickle JE, Milewski M, Cutting GR, Guggino WB, Li M, Stanton BA.

J Biol Chem. 2000 Sep 1;275(35):27069-74.

40.

A PDZ-interacting domain in CFTR is an apical membrane polarization signal.

Moyer BD, Denton J, Karlson KH, Reynolds D, Wang S, Mickle JE, Milewski M, Cutting GR, Guggino WB, Li M, Stanton BA.

J Clin Invest. 1999 Nov;104(10):1353-61.

41.

PBA increases CFTR expression but at high doses inhibits Cl(-) secretion in Calu-3 airway epithelial cells.

Loffing J, Moyer BD, Reynolds D, Stanton BA.

Am J Physiol. 1999 Oct;277(4):L700-8. doi: 10.1152/ajplung.1999.277.4.L700.

PMID:
10516210
42.

Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells.

Moyer BD, Loffing-Cueni D, Loffing J, Reynolds D, Stanton BA.

Am J Physiol. 1999 Aug;277(2):F271-6. doi: 10.1152/ajprenal.1999.277.2.F271.

PMID:
10444582
43.

Exocytosis is not involved in activation of Cl- secretion via CFTR in Calu-3 airway epithelial cells.

Loffing J, Moyer BD, McCoy D, Stanton BA.

Am J Physiol. 1998 Oct;275(4 Pt 1):C913-20.

PMID:
9755044
44.

Membrane trafficking of the cystic fibrosis gene product, cystic fibrosis transmembrane conductance regulator, tagged with green fluorescent protein in madin-darby canine kidney cells.

Moyer BD, Loffing J, Schwiebert EM, Loffing-Cueni D, Halpin PA, Karlson KH, Ismailov II, Guggino WB, Langford GM, Stanton BA.

J Biol Chem. 1998 Aug 21;273(34):21759-68. Erratum in: J Biol Chem 1998 Oct 2;273(40):26256.

45.

Adenosine inhibits arginine vasopressin-stimulated chloride secretion in a mouse IMCD cell line (mIMCD-K2).

Moyer BD, McCoy DE, Lee B, Kizer N, Stanton BA.

Am J Physiol. 1995 Dec;269(6 Pt 2):F884-91.

PMID:
8594884

Supplemental Content

Loading ...
Support Center